Crescent and Kelun-Biotech have entered into a strategic partnership involving the exchange of regional rights for a bispecific antibody from Crescent and an antibody-drug conjugate (ADC) from Kelun. This double deal highlights a significant shift in the competitive landscape of oncology therapeutics, as both companies aim to enhance their portfolios with promising assets that align with their development strategies.
The collaboration underscores the growing trend of asset swapping in the pharmaceutical industry, particularly among companies focused on oncology, where rapid advancements necessitate agile portfolio management. By leveraging each other’s strengths, Crescent and Kelun-Biotech can accelerate their respective drug development timelines and potentially increase market access for their innovative therapies.
This move not only reflects the companies’ commitment to advancing cancer treatments but also signals to investors and stakeholders the importance of strategic partnerships in navigating the complexities of drug development and commercialization in a highly competitive market.
Use the database as your supply chain compass →
